CureVac, in collaboration with GSK, has announced that its second-generation Covid-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.
CV2CoV is a co-development between CureVac and GSK and is based on a new mRNA backbone, which differs from CureVac’s first-generation vaccine candidate, CVnCoV, currently in late-stage clinical testing. Preclinical data in rats immunised with CV2CoV in the dose range of 0.5-40µg demonstrated fast onset of strong immune responses after the first dose. In addition, the serum of vaccinated animals showed significant cross-neutralisation against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351). The full manuscript of the preclinical data is available on the pre-print server bioRxiv.
“mRNA technology has made tremendous progress since the clinical development of first-generation mRNA Covid-19 vaccine candidates started in early 2020,” said Dr Igor Splawski, Chief Scientific Officer of CureVac. “Spurred by the emergence of virus variants that have the potential to affect the efficacy of currently approved first-generation mRNA Covid-19 vaccines, CureVac and GSK aim to jointly develop second-generation vaccine candidates that offer improved immune responses and target emerging variants. Combined with lower doses, these second-generation vaccines could enable also broad protection against selected strains in a multivalent vaccine format.”
Roger Connor, president R&D GSK vaccines said: “To successfully fight the Covid-19 pandemic in the long term, we will need different vaccines and we need to be able to respond effectively to emerging variants. We are pleased with these pre-clinical results as they show the potential of the next generation mRNA technology we are developing together with CureVac.”
CV2CoV is based on a new mRNA backbone that features targeted optimisations designed to improve intracellular mRNA stability and translation for increased and extended protein expression. These optimisations potentially allow for strong immune responses at low doses, which will support the development of multivalent vaccines to target rapidly spreading Covid-19 variants. First clinical trials for CV2CoV are expected to start in the third quarter of 2021.